Babak Hooshmand

Babak Hooshmand

Auto-generated profile, based on publicly available information

Babak Hooshmand

Department of Neurology, Benedictus Klinikum Tutzing and KI-Alzheimer’s Disease Research Center Karolinska Institutet, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2018 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
PDF file
DSDavid Smith
David Smith
HRHelga Refsum
Helga Refsum
TBTeodoro Bottiglieri
Teodoro Bottiglieri
MFMichael Fenech
Michael Fenech
BHBabak Hooshmand
Babak Hooshmand
Rima ObeidRima Obeid
Rima Obeid
Identification of modifiable risk factors provides a crucial approach to the prevention of dementia. Nutritional or nutrient-dependent risk factors are especially important because dietary modifications or use of dietary supplements may lower the risk factor level. One such risk factor is a raised concentration of the biomarker plasma total homocysteine, which reflects the functional status of three B vitamins (folate, vitamins B12, B6). A group of experts reviewed literature evidence from the last 20 years. We here present a Consensus Statement, based on the Bradford Hill criteria, and conclude that elevated plasma total homocysteine is a modifiable risk factor for development of cognitive decline, dementia, and Alzheimer’s disease in older persons. In a variety of clinical studies, the relative risk of dementia in elderly people for moderately raised homocysteine (within the normal range) ranges from 1.15 to 2.5, and the Population Attributable risk ranges from 4.3 to 31%. Intervention trials in elderly with cognitive impairment show that homocysteine-lowering treatment with B vitamins markedly slows the rate of whole and regional brain atrophy and also slows cognitive decline. The findings are consistent with moderately raised plasma total homocysteine (>11 μmol/L), which is common in the elderly, being one of the causes of age-related cognitive decline and dementia. Thus, the public health significance of raised tHcy in the elderly should not be underestimated, since it is easy, inexpensive, and safe to treat with B vitamins. Further trials are needed to see whether B vitamin treatment will slow, or prevent, conversion to dementia in people at risk of cognitive decline or dementia.

8 March 2014 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
ASA. Solomon
A. Solomon
FMF. Mangialasche
F. Mangialasche
ERE. Richard
E. Richard
SAS. Andrieu
S. Andrieu
DBD. A. Bennett
D. A. Bennett
MKM. Kivipelto
M. Kivipelto
Background: Definitions and diagnostic criteria for all medical conditions are regularly subjected to reviews and revisions as knowledge advances. In the field of Alzheimer's disease (AD) research, it has taken almost three decades for diagnostic nomenclature to undergo major re‐examination. The shift towards presymptomatic and pre‐dementia stages of AD has brought prevention and treatment trials much closer to each other than before.Methods: Here we discuss: (i) the impact of diagnostic reliability on the possibilities for developing preventive strategies for AD; (ii) the scientific evidence to support moving from observation to action; (iii) ongoing intervention studies; and (iv) the methodological issues and prospects for balancing strategies for high‐risk individuals with those for broad population‐based prevention.Results: The associations between neuropathology and cognition are still not entirely clear. In addition, the risk factors for AD dementia and the neuropathological hallmarks of AD may not necessarily be the same. Cognitive impairment has a clearer clinical significance and should therefore remain the main focus of prevention. Risk/protective factors for dementia/AD need to be studied from a life‐course perspective. New approaches in prevention trials include enrichment strategies based on genetic risk factors or beta‐amyloid biomarkers (at least four ongoing pharmacological trials), and multidomain interventions simultaneously targeting various vascular and lifestyle‐related risk factors (at least three ongoing trials). Experience from prevention programmes in other chronic diseases can provide additional methodological improvements.Conclusions: Building infrastructures for international collaborations is necessary for managing the worldwide public health problem of AD and dementia. The International Database on Aging and Dementia (IDAD) and the European Dementia Prevention Initiative (EDPI) are examples of ongoing international efforts aiming to improve the methodology of preventive studies and provide the basis for larger intervention trials.

26 August 2013 in Brain
Verified
Journal Article
Open access
PDF file
BHBabak Hooshmand
Babak Hooshmand
TPTuomo Polvikoski
Tuomo Polvikoski
MKMiia Kivipelto
Miia Kivipelto
MTMaarit Tanskanen
Maarit Tanskanen
LMLiisa Myllykangas
Liisa Myllykangas
ASAlina Solomon
Alina Solomon
Elevated plasma total homocysteine is associated with increased risk of dementia/Alzheimer’s disease, but underlying pathophysiological mechanisms are not fully understood. This study investigated possible links between baseline homocysteine, and post-mortem neuropathological and magnetic resonance imaging findings up to 10 years later in the Vantaa 85+ population including people aged ≥85 years. Two hundred and sixty-five individuals had homocysteine and autopsy data, of which 103 had post-mortem brain magnetic resonance imaging scans. Methenamine silver staining was used for amyloid-β and modified Bielschowsky method for neurofibrillary tangles and neuritic plaques. Macroscopic infarcts were identified from cerebral hemispheres, brainstem and cerebellum slices. Standardized methods were used to determine microscopic infarcts, cerebral amyoloid angiopathy, and α-synuclein pathology. Magnetic resonance imaging was used for visual ratings of the degree of medial temporal lobe atrophy, and periventricular and deep white matter hyperintensities. Elevated baseline homocysteine was associated with increased neurofibrillary tangles count at the time of death: for the highest homocysteine quartile, odds ratio (95% confidence interval) was 2.60 (1.28–5.28). The association was observed particularly in people with dementia, in the presence of cerebral infarcts, and with longer time between the baseline homocysteine assessment and death. Also, elevated homocysteine tended to relate to amyloid-β accumulation, but this was seen only with longer baseline-death interval: odds ratio (95% confidence interval) was 2.52 (0.88–7.19) for the highest homocysteine quartile. On post-mortem magnetic resonance imaging, for the highest homocysteine quartile odds ratio (95% confidence interval) was 3.78 (1.12–12.79) for more severe medial temporal atrophy and 4.69 (1.14–19.33) for more severe periventricular white matter hyperintensities. All associations were independent of several potential confounders, including common vascular risk factors. No relationships between homocysteine and cerebral macro- or microinfarcts, cerebral amyoloid angiopathy or α-synuclein pathology were detected. These results suggest that elevated homocysteine in adults aged ≥85 years may contribute to increased Alzheimer-type pathology, particularly neurofibrillary tangles burden. This effect seems to be more pronounced in the presence of cerebrovascular pathology. Randomized controlled trials are needed to determine the impact of homocysteine-lowering treatments on dementia-related pathology.

19 October 2010 in Neurology
Verified
Journal Article
Closed access
PDF file
BHB. Hooshmand
B. Hooshmand
ASA. Solomon
A. Solomon
IKI. Kåreholt
I. Kåreholt
JLJ. Leiviskä
J. Leiviskä
MRM. Rusanen
M. Rusanen
MKM. Kivipelto
M. Kivipelto
Objective: To examine the relation between serum levels of homocysteine (tHcy) and holotranscobalamin (holoTC), the active fraction of vitamin B12, and risk of incident Alzheimer disease (AD) in a sample of Finnish community-dwelling elderly. Methods: A dementia-free sample of 271 subjects aged 65–79 years derived from the Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) study was followed up for 7 years to detect incident AD. The association between serum tHcy and holoTC with AD was analyzed with multiple logistic regression after adjusting for several potential confounders, including common vascular risk factors. Results: The odds ratios (ORs) (95% confidence interval [CI]) for AD were 1.16 (1.04–1.31) per increase of 1 μmol/L of tHcy at baseline and 0.980 (0.965–0.995) for each increase of 1 pmol/L baseline holoTC. Adjustment for several potential confounders including age, sex, education, APOE ϵ4 allele, body mass index, Mini-Mental State Examination, smoking, stroke, and blood pressure did not alter the associations: ORs (95% CI) for AD became 1.19 (1.01–1.39) for tHcy and 0.977 (0.958–0.997) for holoTC. Adjusting for holoTC attenuated the tHcy–AD link (OR changed from 1.16 to 1.10, 95% CI 0.96–1.25). The holoTC–AD relationship was less influenced by controlling for tHcy (OR changed from 0.980 to 0.984, 95% CI 0.968–1.000). Addition of folate did not change any of the results. Conclusions: This study suggests that both tHcy and holoTC may be involved in the development of AD. The tHcy–AD link may be partly explained by serum holoTC. The role of holoTC in AD should be further investigated.

1 December 2013 in Experimental Gerontology
Verified
Journal Article
Closed access
FMFrancesca Mangialasche
Francesca Mangialasche
ASAlina Solomon
Alina Solomon
IKIngemar Kåreholt
Ingemar Kåreholt
BHBabak Hooshmand
Babak Hooshmand
RCRoberta Cecchetti
Roberta Cecchetti
MKMiia Kivipelto
Miia Kivipelto

1 June 2016 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
BHBabak Hooshmand
Babak Hooshmand
FMFrancesca Mangialasche
Francesca Mangialasche
GKGrégoria Kalpouzos
Grégoria Kalpouzos
ASAlina Solomon
Alina Solomon
IKIngemar Kåreholt
Ingemar Kåreholt
MKMiia Kivipelto
Miia Kivipelto
Vitamin B12 and folate are closely connected with the metabolism of homocysteine, a sulfur-containing nonessential amino acid. Inadequate levels of either vitamin can result in increased concentrations of total homocysteine (tHcy).1 High levels of tHcy and low levels of vitamin B12 and folate are common in the elderly and are associated with a variety of disorders, including cardiovascular and cerebrovascular conditions.2-5 In addition, they may influence brain structure through several mechanisms.4 In older adults, substantial cerebral atrophy is associated with a diagnosis of dementia, which is maintained in very advanced age.6,7 Whereas few longitudinal studies have linked low vitamin B12 or folate levels with structural brain changes,8,9 others did not report such associations.9-11 Higher blood levels of tHcy have also been associated with an increased rate of brain atrophy10-14 and progression of white matter lesion volume,15 although the evidence is inconsistent.9,11